Latest Health News

PolarX Limited's trading suspension has been lifted immediately following its announcement of a new capital raising, signaling renewed market activity for the mining explorer.

Rewardle Holdings reported a modest revenue increase for FY25 but saw its loss more than double, driven by investments in AI-powered MedTech associate CloudHolter and expanded platform initiatives.

4DMedical has secured multi-year agreements to deploy its advanced lung imaging technology across Brazil and Australia, supporting national lung cancer screening programs and enhancing lung health diagnostics.

Proteomics International has unveiled new clinical data confirming its PromarkerEso blood test can accurately detect early stages of esophageal adenocarcinoma, potentially transforming screening for a cancer with poor prognosis.

Rubix Resources (ASX, RB6) has resumed trading after lifting its suspension, following key announcements on its drilling program, capital raising, and a proposed acquisition.

Carnegie Clean Energy has secured a pivotal role in a €4 million European Commission-funded project aimed at advancing wave energy technology and reducing costs. The initiative leverages Carnegie’s CETO platform to pioneer innovations that could reshape the future of ocean energy farms.

PYC Therapeutics has completed dosing in its Phase 1 study of PYC-001 for Autosomal Dominant Optic Atrophy, showing strong safety and early signs of improved vision. The company plans to launch a global Phase 1/2 trial later this year.

Wesfarmers Limited has updated its dividend details, confirming a fully franked ordinary dividend of AUD 1.11 per share payable on 7 October 2025, with shareholders able to receive payments in AUD, NZD, or GBP.

The Calmer Co. reports a significant operational turnaround in H2 FY25, with sales momentum building through July and August, driven by cost reductions and new product launches in the US market.

Haranga Resources has successfully commissioned the water treatment plant at its Lincoln Gold Project and begun dewatering, paving the way for its maiden underground drilling program and a JORC resource update by year-end.

Tasmea Limited has firmly denied recent media speculation about potential block trades by its executive directors, reaffirming their strong shareholding and commitment to growth. The company is focused on organic expansion and acquisitions to secure ASX 300 inclusion next year without raising new capital.

Biome Australia Limited projects its Q1 FY26 sales revenue to exceed $5.5 million, breaking its previous quarterly record and signaling continued momentum in the microbiome health sector.